Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Studio City (新濠影汇) IPO Trading Update: Performance Within Expectations, Near-Term Upside Capped

Studio City (新濠影汇) IPO: Attractive Valuation with Options for Long-Term Upside (Part 2)

Studio City (新濠影汇) IPO: A Melco Spin-Off Turning Profitable

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Studio City International Holdings Limited / Equity Capital Markets

Studio City International Holdings Limited (MSC US)

Studio City International Holdings Limited

<p>Studio City, a spin-off by MLCO US, was listed on October 18th, 2018 and its lock-up will expire next week on April 16th. The company raised USD 359 million in its IPO with the majority of the shares taken up by its shareholders.</p>
<p>In this insight, we will review the company's operation, shares subject to lock-up expiry and its valuation vs peers. </p>
<hr>
<h2>Our previous insights on Studio City</h2>
<ul>
<li><a href="https://www.smartkarma.com/insights/studio-city-ipo-a-melco-spin-off-turning-profitable" target="_blank" data-smartkarma-citation="insights:24698">Studio City (新濠影汇) IPO: A Melco Spin-Off Turning Profitable</a></li>
<li><a href="https://www.smartkarma.com/insights/studio-city-ipo-attractive-valuation-with-options-for-long-term-upside-part-2" target="_blank" data-smartkarma-citation="insights:24922">Studio City (新濠影汇) IPO: Attractive Valuation with Options for Long-Term Upside (Part 2)</a></li>
<li><a href="https://www.smartkarma.com/insights/studio-city-ipo-trading-update-performance-within-expectations-near-term-upside-capped" target="_blank">Studio City (新濠影汇) IPO Trading Update: Performance Within Expectations, Near-Term Upside Capped</a></li>
</ul>

Studio City, a spin-off by MLCO US, was listed on October 18th, 2018 and its lock-up will expire next week on April 16th. The company raised USD 359 million in its IPO with the majority of the shares taken up by its shareholders.
In this insight, we will review the company's operation, shares subject to lock-up expiry and its valuation vs peers. 

Our previous insights on Studio City

Studio City (新濠影汇) IPO: A Melco Spin-Off Turning Profitable
Studio City (新濠影汇) IPO: Attractive Valuation with Options for Long-Term Upside (Part 2)
Studio City (新濠影汇) IPO Trading Update: Performance Within Expectations, Near-Term Upside Capped


Studio City International Holdings Limited

Studio City - Thoughts on Lock-Up Expiry